Follows pregnant women with migraine who take erenumab
Tracks babies born to women with migraine who took erenumab during pregnancy.
Key facts
- Who runs it
- Amgen
- Where
- Durham, United StatesSee the site
- Trial code
- Registry title
- Aimovig Pregnancy Exposure Registry
- Status
- Recruiting
- People taking part
- 2,842 people, planned
- Started
- 27 Jan 2021
- Expected to end
- 28 Oct 2027
- Type of study
- Observational, 3 groups
- Treatments tested
- erenumab-aooe
- Record updated
- 4 November 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women aged 18 or older with a confirmed migraine diagnosis. It follows birth outcomes in women who did or did not take erenumab-aooe.
- Age
- 18 years or older (up to 99 years).
- Sex
- Women only.
- Disease stage
- Confirmed clinical diagnosis of migraine. The pregnancy outcome must not be known yet.
- Earlier treatment
- The trial looks at women who took erenumab-aooe before or during pregnancy, and women who did not. Women who took other medicines that target the CGRP pathway (CGRP monoclonal antibody or gepants) from 5 half-lives before the last menstrual period through the end of pregnancy cannot join.
Main reasons for not taking part
- Taking part in another investigational device or drug study
- Taking an investigational medicine now, or within 3 months before the last menstrual period or during pregnancy
- Taking CGRP-targeting medicines (CGRP monoclonal antibody or gepants) from 5 half-lives before the last menstrual period through the end of pregnancy
This trial only enrols pregnant participants. The registry sentence this rests on: Currently pregnant
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age 18 years or older (at time of signing the informed consent)
- Currently pregnant
- The outcome of the pregnancy must not be known
- Confirmed clinical diagnosis of migraine
Who cannot take part
- Women currently participating in another investigational device or investigational drug study, currently taking an investigational medicinal product, or having taken an investigational product within 3 months prior to last menstrual period (LMP) or during pregnancy. Other investigational procedures while participating in this study are excluded
- Women exposed to any medications that target the calcitonin gene-related peptide (CGRP) pathway (ie, CGRP monoclonal antibody [mAb] or gepants) in the period from 5 half-lives prior to LMP through the end of pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Where in United States
- Durham, North CarolinaHospital not named in the registryTaking people
About the trial
What the trial wants to find out
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
The 3 groups in the trial
- Erenumab-aooe-exposed
Pregnant women with confirmed migraine who received erenumab-aooe before or during pregnancy will qualify to be included in the cohort. Dosing and treatment duration of erenumab-aooe as part of this observational study is at the discretion of the healthcare provider (HCP) in accordance with local clinical practice and local labeling.
Treatment: erenumab-aooe
- Erenumab-aooe-unexposed (Internal Comparator)
Pregnant women with clinically confirmed migraine who were not exposed to erenumab-aooe before or during pregnancy will be included in the internal comparator cohort.
- Women Without Migraine (External Comparator)
Pregnant woman without migraine will be included in this cohort as external comparator. The Metropolitan Atlanta Congenital Defects Program (MACDP) birth defects classification system will be used to characterize major and minor congenital malformations for this study.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- GENESIS: AIMOVIG® Pregnancy Exposure Registry
- Plain-language title
- Follows pregnant women with migraine who take erenumabGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06150781, who can take part
- Record updated
- 4 November 2025